Citryll is a biotech company developing innovative therapies for immune-mediated inflammatory diseases by targeting Extracellular Traps
Citryll is a biotech company developing innovative therapies for immune-mediated inflammatory diseases by targeting Extracellular Traps. It raised EUR 85 million in Series B funding and is conducting clinical trials for its lead asset, CIT-013.